2009;160;206-209.

２．Department of Virology Ⅱ6)

Oka T, Miyashita K, Katayama K, Wakita T,Takeda

1)

N.

Distinct

genotype

andYoshida T, Kasuo S, Azegami Y, Uchiyama Y,antigenicity

among

genogroupII

Satsumabayashi K, Shiraishi T, Katayama K,

sapoviruses.

MicrobiolWakita

53(7):417-20, 2009.

T,

TakedaN,OkaT.

Characterization of sapoviruses detectedin2)

3)

gastroenteritis

outbreaks

andTakeda N, Katayama K. Development of abroadly

with high viral load. J Clin Virol.

transcription-PCR assay to detect murine

45(1):67-71. 2009.

noroviruses, and investigation of theOotsuka Y, Yamashita Y, Ichikawa T, Kondo

prevalence

ofmurineR, Oseto M, Katayama K, Takeda N, Oka T.

laboratory

mice

in

Molecularcharacterization

Immunol. 53(9):531-4. 2009

sapoviruses

detectedinofsporadic8)

reactive

nestedreversenoroviruses
Japan.

inMicrobiol

Oka T, Yokoyama M, Katayama K, Tsunemitsu

gastroenteritis cases in 2007 in Ehime

H, Yamamoto M, Miyashita K, Ogawa S,Prefecture, Japan. Jpn J Infect Dis.

Motomura K, Mori H, Nakamura H, Wakita T,62(3):246-8. 2009.

TakedaIwakiri A, Ganmyo H, Yamamoto S, Otao K,

biological constraints on diversity ofMikasa M, Kizoe S, Katayama K, Wakita T,

regions immediately upstream of cleavage

Takeda N, Oka T. Quantitative analysis ofsites in calicivirus precursor proteins.

fecal sapovirus shedding: identification

Virology. 394(1):119-29. 2009.
9)

N,SatoH.

StructuralandSomeya Y, Takeda N: Insights into theprotein during prolonged excretion. Arch

Enzyme-SubstrateVirol. 154(4):689-93. 2009.

Norovirus 3C-like Protease. J Biochem

Harada S, Okada M, Yahiro S, Nishimura K,

146: 509-521, 2009.

Interaction

intheMatsuo S, Miyasaka J, Nakashima R, Shimada10) Murakami K, Suzuki S, Aoki N, Okajima T,Y, Ueno T, Ikezawa S, Shinozaki K,Nadano D, Uchida K, Yamashita K, Oka T,

Katayama K, Wakita T, Takeda N, Oka T.

Katayama K, Takeda N, Matsuda T. Binding

Surveillance of pathogens in outpatientsof Norovirus virus-like particles (VLPs)

withandto human intestinal Caco-2 cells and thecharacterization of sapovirus strains

suppressive effect of pasteurized bovine

betweengastroenteritis
2002

Prefecture,and2007

inKumamotocolostrum on this VLP binding. Bioscience,Japan.

JMedVirol.

Biotechnology, and Biochemistry. 74(3):81(6):1117-27. 2009.
5)

Kitajima M, Oka T, Tohya Y, Katayama H,

identification of asymptomatic adultsof nucleotide substitutions in the capsid

4)

7)

Immunol.

541-547.2010.

Eiji Haramoto, Hiroyuki Katayama, Etsuko

11) Zhang Y, Wang H, Zhu S, Li Y, Song L, Liu Y, Liu

Utagawa, Shinichiro Ohgaki. Recovery ofG, Nishimura Y, Chen L, Yan D, Wang D, An H,

human norovirus from water by virus

Shimizu H, Xu A Xu W. Characterization of a rare

concentration methods. J Virol Methods,

natural1intertypic

type2/type3penta-recombinantvaccine-derived

isolatedchildfromawith

Recombinant Viral Antigens of Various

poliovirus

acute

Genotypes. J Clin Microb 47: 4141-4143,flaccid

2009.

paralysis. J Gen Virol 91: 421-429, 2010.
12) Thorley B, Kelly H, Nishimura Y, Yoon YK, Brussen

19) Hara H, Aizaki H, Matsuda M, Shinkai-Ouchi F,KA, Roberts J Shimizu H. Oral poliovirus vaccine

Inoue Y, Murakami K, Shoji I, Kawakami H,

type 3 from a patient with transverse myelitis isMatsuura Y, Lai MMC, Miyamura T, Wakita T, Suzuki

neurovirulent in a transgenic mouse model. J Clin

T: Involvement of creatine kinase B in hepatitis

Virol 44: 268-271, 2009.

C virus genome replication through interaction13) Nishimura Y, Shimojima M, Tano Y, Miyamura T,

with the viral NS4A protein. J Virol 83: 5137-47,

Wakita T Shimizu H. Human P-selectin glycoproteinligand-1 is a functional receptor for enterovirus

2009.
20) Shimoji T, Murakami K, Sugiyama Y, Matsuda M,

71. Nat Med 15: 794-797, 2009.

Inubushi S, Nasu J, Shirakura M, Suzuki T, Wakita

14) Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N,T, Kishino T, Hotta H, Miyamura T, Shoji I:Itagaki T, Ohmi A, Okamoto M, Nishimura H,

Identification

Matsuzaki Y, Hongo S, Sugawara K, Shimizu H Ahiko

substrate for E6AP-mediated ubiquitylation. JT. Cross-antigenicity among EV71 strains fromCellular Biochemistry, 106: 1123-1135, 2009.

different genogroups isolated in Yamagata, Japan,21) Hmwe S, Aizaki H, Date T, Murakami K, Ishii K,

between 1990 and 2007. Vaccine 27: 3153-3158,

Miyamura T, Koike K, Wakita T and Suzuki T:

2009.

Identification of hepatitis C virus genotype 2a15) Goto K, Sanefuji M, Kusuhara K, Nishimura Y,
Shimizu

H,

KiraR,TorisuHHaraannexinA1

asanovel

replicon variants with reduced susceptibility toT.

Rhombencephalitis and coxsackievirus A16. Emergofribavirin. Antiviral Res 85: 520-524, 2010.
22) Kiyohara T, Totsuka A, Ishii K, Ito T, and Wakita

Infect Dis 15: 1689-1691, 2009.

T:Characterizationofanti-idiotypic16) Arita M, Wakita T Shimizu H. Cellular kinase

antibodies mimicking the antibody-binding site

inhibitors that suppress enterovirus replicationand the receptor-binding site on hepatitis A

have a conserved target in viral protein 3Avirus. Arch Virol 154:1263-1269, 2009.

similar to that of enviroxime. J Gen Virol 90:23)

1869-1879, 2009.

Kiyohara T, Ouchi Y, Sato T, Yoneyama T, Ishii
K, Ito T, and Wakita T: Evaluation of an in-house17) Arita M, Ling H, Yan D, Nishimura Y, Yoshida H,

anti-hepatitis

Avirus(HAV)-specificWakita T Shimizu H. Development of a reverse

immunoglobulinM

captureenzyme-linked

transcription-isothermal

immunosorbent assay kit and its practical use foramplification (RT-LAMP) system for a highly

analysis of an HAV outbreak. J Med Virol 81:1513-6,

sensitive detection of enterovirus in the stool

2009.

loop-mediatedsamples of acute flaccid paralysis cases. BMC24) Masaki T, Suzuki R, Saeed M, Mori K, Matsuda M,

Infect Dis 9: 208, 2009.

Aizaki H, Ishii K, Maki N, Miyamura T, Matsuura18) Saeed M, Suzuki R, Kondo M, Aizaki H, KatoM, Wakita T, and Suzuki T: Production ofT, Mizuochi T, Wakita T, Watanabe H,

infectious hepatitis C virus by using RNA

Suzuki T: Evaluation of Hepatitis C Viruspolymerase I-mediated transcription. J Virol 84:

Core5824-5835, 2009.

AntigenAssaysinDetecting25) Zhang YY, Zhang BH. Ishii K and Liang TJ. A novel2function of CD81 in controlling hepatitis C virus

virus 2a in Huh-7 cells with a defective

replication. J Virol, 84: 3396-3407, 2009.

Jak-Stat pathway. Virol J. 7(1): 36, 2010.

26) Ishii K. Hasegawa H, Nagata N, Ami Y, Fukushi S,Taguchi

F,and

Tsunetsugu-Yokota

32)

2',5'-Oligoadenylate synthetase-likeY:

Vaccine-induced neutralizing antibody against

gene highly induced by hepatitis C virus

SARS-CoV Spike is highly effective for theinfection in human liver is inhibitory toprotection of mice in the murine SARS model.

viral replication in vitro. Biochem

Microbiol Immunol 53: 75-82, 2009.

Biophys Res Commun. 392(3): 397-402,2010.

27) Suzuki R, Moriishi K, Fukuda K, Shirakura M, Ishii
K, Shoji I, Miyamura T. Matsuura M, Suzuki T:

33)

Liu X, Wang T, Wakita T, Yang W. SystematicProteasomal turnover of hepatitis C virus coreidentification of microRNA and messenger

protein is regulated by two distinct mechanisms:

RNA profiles in hepatitis Cubiquitin-dependent and ubiquitin independent

virus-infected human hepatoma cells.

but PA28g-dependent. J Virol 83: 2389-2392, 2009.

Virology. 398(1): 57-67, 2010.

28) Yamashita T, Mori Y, Miyazaki N, Cheng RH,34)

Angus AG, Dalrymple D, Boulant S, McGivern

Yoshimura M, Unno H, Shima R, Moriishi K,DR, Clayton RF, Scott MJ, Adair R, Graham

Tsukihara T, Li TC, Takeda N, Miyamura T, Matsuura

S, Owsianka AM, Targett-Adams P, Li K,

Y: Biological and immunological characteristics

Wakita T, McLauchlan J, Lemon SM, Patel AH.

of hepatitis E virus-like particles based on theRequirement of cellular DDX3 forcrystal structure. Proc Natl Acad Sci U S A. 106:hepatitis C virus replication is12986-91, 2009.

unrelated to its interaction with theviral core protein. J Gen Virol. 91(1):29) Sugitani M, Tamura A, Shimizu YK, Sheikh A,

122-32, 2010.

Kinukawa N, Shimizu K, Moriyama M, Komiyama K,Li TC, Takeda N, Arakawa Y, Suzuki K, Ishaque SM,35)

Seronello S, Ito C, Wakita T, Choi J.

Roy PK, Raihan A, Hasan M: Detection of hepatitis

Ethanol enhances hepatitis C virusE virus RNA and genotype in Bangladesh. J

replication through lipid metabolism andGastroenterol Hepatol 24: 599-604, 2009.

elevated NADH/NAD+. J Biol Chem. 285(2):845-54, 2010.

30) Sugitani M, Sheikh A, Suzuki K, Kinukawa N,Moriyama M, Arakawa Y, Komiyama K, Li TC, Takeda

36)

Abe K, Ikeda M, Ariumi Y, Dansako H, Wakita

N, Ishaque SM, Roy PK, Raihan AS, Hasan M:

T, Kato N. HCV genotype 1b chimeric

Sero-epidemiology of sporadic acute hepatitis inreplicon with NS5B of JFH-1 exhibitedBangladesh: high prevalences of infection withresistance to cyclosporine A. Arch Virol.

type-B, type-E and multiple types of hepatitis

154 (10): 1671-7, 2009.

virus. Ann Trop Med Parasitol 103: 343-50, 2009.
31)

Ishibashi M, Wakita T, Esumi M.

37)

Hiraga N, Imamura M, Hatakeyama T,

Hazari S, Chandra PK, Poat B, Datta S,

Kitamura S, Mitsui F, Tanaka S, Tsuge M,

Garry RF, Foster TP, Kousoulas G, Wakita

Takahashi S, Abe H, Maekawa T, Ochi H,T, Dash S. Impaired antiviral activity ofTateno C, Yoshizato K, Wakita T, ChayamaK.

interferon alpha against hepatitis C

Absence of viral interference anddifferent susceptibility to interferon3between hepatitis B virus and hepatitis C38)

44)

virus in human hepatocyte chimeric mice.

SB. Hepatitis C virus nonstructural 4B

J Hepatol. 51(6): 1046-54, 2009.

protein modulates sterol regulatory

Kato N, Mori K, Abe KI, Dansako H, Kuroki

element-binding protein signaling via theM, Ariumi Y, Wakita T, Ikeda M. Efficient

AKT pathway. J Biol Chem. 3;284(14):replication systems for hepatitis C virus

9237-46, 2009.

using a new human hepatoma cell line.
Virus Res. 146(1-2): 41-50, 2009.
39)

Tanida I, Fukasawa M, Ueno T, Kominami E,Wakita T, Hanada K. Knockdown of
autophagy-related gene decreases theproduction of infectious hepatitis Cvirus particles. Autophagy. 5(7): 937-45,2009.

40)

Murakami Y, Noguchi K, Yamagoe S, SuzukiT, Wakita T, Fukazawa H. Identification ofbisindolylmaleimides andindolocarbazoles as inhibitors of HCV
replication by tube-capture-RT-PCR.
Antiviral Res. 83(2): 112-7, 2009.

41)

Kang JI, Kim JP, Wakita T, Ahn BY. Cell
culture-adaptive mutations in the NS5B
gene of hepatitis C virus with delayed
replication and reduced cytotoxicity.
Virus Res. 144(1-2): 107-16, 2009.

42)

Dansako H, Ikeda M, Ariumi Y, Wakita T,
Kato N.

Double-stranded RNA-inducedinterferon-beta and inflammatory
cytokine production modulated byhepatitis C virus serine proteases
derived from patients with hepaticdiseases. Arch Virol. 154(5): 801-10,
2009.
43)

Park CY, Jun HJ, Wakita T, Cheong JH, Hwang

Weng L, Du J, Zhou J, Ding J, Wakita T,Kohara M, Toyoda T. Modification ofhepatitis C virus 1b RNA polymerase to
make a highly active JFH1-type polymeraseby mutation of the thumb domain. ArchVirol. 154(5): 765-73, 2009.

4